Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement
- Details
- Category: Boehringer Ingelheim
Elan plc (NYSE: ELN) and Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.
Sanofi-aventis' fourth-quarter and full-year net sales
- Details
- Category: Sanofi
In the fourth quarter of 2010, sanofi-aventis generated net sales of €7,395 million, up 0.5% on a reported basis. Exchange rate movements had a favorable effect of 6.4 percentage points, mainly due to the weaker euro versus the U.S. dollar, Japanese Yen, Brazilian Real, and Australian dollar.
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET
- Details
- Category: Novartis
The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].
FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
- Details
- Category: Bayer
Bayer HealthCare announced that its investigational anti-cancer compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
GSK revises US Avandia label to include new restrictions on use
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines.
Pfizer To Acquire Ferrosan's Consumer Healthcare Business
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has entered into a definitive agreement to purchase Ferrosan's consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.
More Pharma News ...
- Nycomed to acquire Colombian company Farmacol
- New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
- GSK's full year trading update
- The Roche Group posted solid overall results in 2010
- Novo Nordisk increased operating profit by 27% in 2010
- Pfizer Reports Fourth-Quarter and Full-Year 2010 Results
- Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.